SGLT-2 inhibition in patients with kidney disease

Diabetes and Metabolism

Volumn 40, Issue 6, 2014, Pages S23-S27

  Gilbert, R E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Diabetes; Kidney; Kidney disease; Renal failure; SGLT 2 inhibitors

Indexed keywords

GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADVERSE DRUG REACTION; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY TUBULE PRESSURE; OUTCOME ASSESSMENT; RENAL PROTECTION; URIC ACID BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; HYPERGLYCEMIA; KIDNEY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; URINARY EXCRETION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; MEMBRANE TRANSPORT MODULATORS; RENAL ELIMINATION; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84928411917     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(14)72692-8     Document Type: Article

References (22)

1. Moe O.W., Wright S.H., Palacin M. Renal handling of organic solutes. Brenner and Rector's the Kidney 2012, 252-292. Elsevier, Philadelphia, PA. 9th. A. MWTe (Ed.).
2. Farber S.J., Berger E.Y., Earle D.P. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951, 30:125-129.
3. Mogensen C.E. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scandinavian journal of clinical and laboratory investigation 1971, 28:101-109.
4. Santer R., Calado J. Familial renal glucosuria and SGLT-2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010, 5:133-141.
5. Polidori D., Sha S., Ghosh A., Plum-Morschel L., Heise T., Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism 2013, 98:E867-E871.
6. Toka H.R., Yang J., Zera C.A., Duffield J.S., Pollak M.R., Mount D.B. Pregnancy-associated polyuria in familial renal glycosuria. Am J Kidney Dis 2013, 62:1160-1164.
7. Yale J.F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
8. Kohan D.E., Fioretto P., Tang W., List J.F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014, 85:962-971.
9. Barnett A.H., Mithal A., Manassie J., Jones R., Rattunde H., Woerle H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology 2014, 2:369-384.
10. Ferrannini E., Veltkamp S.A., Smulders R.A., Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2013, 36:1260-1265.
11. Gilbert R.E. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int 2014, 86:693-700.
12. Gilbert RE. Reply to 'sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes'. Kidney Int 2014 (In Press).
13. Yale J.F., Bakris G., Cariou B., Nieto J., David-Neto E., Yue D., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014, 16:1016-1027.
14. Gilbert R.E., Mann J.F., Hanefeld M., Spinas G., Bosch J., et al. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014, 57:1325-1331. ORIGIN trial investigators.
15. Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59.
16. Parving H.H., Andersen E.R., Smidt U., Hommel E., Mathiesen E. Antihypertensive treatment postpones endstage renal failure in diabetic nephropathy. Br Med J 1987, 294:1443-1447.
17. Zinman B., Inzucchi S.E., Lachin J.M., Wanner C., Ferrari R., Fitchett D., et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014, 13:102.
18. I. Prescribing information Accessed October 6, 2014. 2014. http://www.invokanahcp.com/prescribing-information.pdf.
19. Farxiga. Prescribing information. - page=1 Accessed October 6, 2014. 2014. http://www.astrazeneca-us.com/pi/pi_farxiga.pdf-page=1.
20. (empagliflozin) J. Prescribing information. Accessed October 6, 2014. 2014. http://bidocs.boehr%20inger-ingelheim.com/BIWebAccess/ViewServlet.ser%3FdocBase=renetnt%26folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf.
21. Kohan D., Fioretto P., Tang W., List J. Long-term Randomized Study (104 weeks) of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment who have Inadequate Glycemic Control. Kidney Int 2014, 85:962-971.
22. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News in physiological sciences: an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society 2003, 18:169-174.